- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02535624
Retroperitoneal Packing or Angioembolization for Hemorrhage Control of Pelvic Fractures
Retroperitoneal Packing or Angioembolization for Hemorrhage Control of Pelvic Fractures - Quasi-randomized Clinical Trial of 56 Hemodynamically Unstable Patients With Injury Severity Score ≥ 33
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
In patients with pelvic fracture uncontrollable bleeding is the major cause of death within the first 24h after injury. Early hemorrhage control is therefore vital for successful treatment. Nowadays, recommended techniques for hemorrhage control in pelvic fractures are retroperitoneal pelvic packing and angioembolization, dependent upon the available technical staff and resources and the condition of the patient.
Retroperitoneal pelvic packing, on the one hand, is a relatively simple method in controlling pelvic hemorrhage even with limited resources. Since 89% of pelvic fracture hemorrhage originates from venous bleeding, fracture stabilization and compressive hemostasis by packing is a reasonable approach. Angioembolization, on the other hand, has great high effectiveness with regard to bleeding control, but requires an angiography suite and technical staff. Since hemostasis of retroperitoneal venous bleeding often can be achieved by external pelvic fixation, angioembolization is required for the 11% arterial bleedings which are hard to control by packing. Even though many authors see both methods as complements, time is crucial in the multitrauma setting and the severely injured patient does not tolerate multiple interventions well. Until now good predictors for treatment choice are unavailable, and management of hemodynamically unstable pelvic fractures remains a matter of debate.
This study was designed to answer following questions:
- Is retroperitoneal pelvic packing or angiography superior with regard to in-hospital mortality, complications, required secondary procedures, or post-intervention blood loss?
- Which of these methods is the more rapid intervention in the acute setting?
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Shandong
-
Jinan, Shandong, China, 250021
- Shandong Provincial Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- multitrauma defined as Injury Severity Score (ISS) > 17
- dislocated pelvic fracture type B or C according to Tile[10] on emergency department pelvic radiograph
- hemodynamic instability defined as systolic blood pressure (SBP) <90 mmHg after administration of 4 units of packed red blood cells (PRBC).
Exclusion Criteria:
- monotrauma, or ISS ≤ 17
- age > 65 years
- age < 18 years
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: ANGIO
Patients with persistent hemodynamic instability (systolic blood pressure (SBP) <90 mmHg after the transfusion of 4 packed red blood cell (PRBC) units in the emergency department) were taken urgently to the angiography suite for pelvic angiography.
These patients had to tolerate transfer to the suite.
Patients receiving primarily angioembolization therapy were defined as the ANGIO group.
|
Using en endovascular approach, bleeding arteries are identified and clotted using embolizing agents, or coils.
Other Names:
|
Active Comparator: PACKING
Indication for pelvic packing was persistent SBP<90 mmHg during the initial resuscitation period with 3000 ml of intravenous (IV) crystalloids and transfusion of 4 PRBC units.
These patients were treated primarly with retroperitoneal packing, while angioembolization OR staff was unavailable (5pm-7am), and were defined as the PACK group.
|
By retroperitoneal access the space in front of the pelvic fracture is compressed with surgical towels, which stops effectively venous bleeding
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of participants deceased occurring in-hospital during or after treatment with packing or embolization
Time Frame: participants will be followed for the duration of hospital stay, an expected average of 6 weeks
|
participants will be followed for the duration of hospital stay, an expected average of 6 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants with Adverse Events as a Measure of Safety and Tolerability
Time Frame: participants will be followed for the duration of hospital stay, an expected average of 6 weeks
|
participants will be followed for the duration of hospital stay, an expected average of 6 weeks
|
|
Number of postoperative packed red blood cell units administered for each participant
Time Frame: participants will be followed for the duration of hospital stay, an expected average of 6 weeks
|
participants will be followed for the duration of hospital stay, an expected average of 6 weeks
|
|
Number of participants which required a secondary procedure (PACKING or ANGIO) after the primary intervention (PACKING or ANGIO)
Time Frame: participants will be followed for the duration of hospital stay, an expected average of 6 weeks
|
Packing for ANGIO and angioembolization for PACKING.
|
participants will be followed for the duration of hospital stay, an expected average of 6 weeks
|
Time from admission (in minutes) to treatment (PACKING or ANGIO) for each participant
Time Frame: participants will be followed for the duration of hospital stay, an expected average of 6 weeks
|
participants will be followed for the duration of hospital stay, an expected average of 6 weeks
|
|
Procedural/surgical time (in minutes) for each participant
Time Frame: participants will be followed for the duration of hospital stay, an expected average of 6 weeks
|
participants will be followed for the duration of hospital stay, an expected average of 6 weeks
|
|
Days on ICU for each participant
Time Frame: participants will be followed for the duration of hospital stay, an expected average of 6 weeks
|
participants will be followed for the duration of hospital stay, an expected average of 6 weeks
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Director: Dongsheng Zhou, MD, PhD, Shandong Provincial Hospital
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- PELVIC001
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Fractures, Bone
-
Lawson Health Research InstituteCompleted
-
AO Innovation Translation CenterRecruitingLong Bone FracturesUnited States, Canada, Australia, Ghana, Chile, China, Germany, India, Pakistan, Venezuela, Spain, Croatia, Greece
-
University Hospital, Clermont-FerrandRecruiting
-
Centre Hospitalier Universitaire Saint PierreRecruiting
-
McMaster UniversityMcMaster Surgical AssociatesCompleted
-
IlluminOss Medical, Inc.CompletedHumerus Fracture Metastatic Bone DiseaseUnited States
-
University of UtahCompletedBone Strength | Stress Fractures | Bone Geometry | Biomechanical ChangesUnited States
-
University of British ColumbiaCompleted
-
Novo Nordisk A/SCompletedBone Fracture | Tibia FracturesIsrael, Germany, Finland, Hungary, Spain, South Africa, Norway, France, Poland
-
Carlos A Acosta-OlivoCompletedRadius Fractures | Bone Fractures | Closed Fractures
Clinical Trials on ANGIO
-
ECRI bvBoston Scientific CorporationActive, not recruitingComplex Coronary LesionsSpain, United Kingdom, Netherlands, France, Belgium, Germany, Italy
-
First Affiliated Hospital of Harbin Medical UniversityUnknownCoronary Artery DiseaseChina
-
CHU de ReimsCompletedAbdominal Aortic AneurysmFrance
-
Abbott Medical DevicesCompletedPatients Requiring a Diagnostic and/or Interventional Diagnostic ProcedureGermany
-
Azienda Ospedaliera Sant'Anna e San SebastianoUnknownCoronary Artery Disease | Percutaneous Coronary Intervention | STEMI - ST Elevation Myocardial InfarctionItaly
-
University Hospital of FerraraCompletedStents | PrognosisItaly, Spain
-
Abbott Medical DevicesTerminatedVascular Access ComplicationSpain, Portugal
-
Hospital Vall d'HebronTerminated
-
Xiongjing JiangRecruitingPeripheral Vascular Diseases | Percutaneous Intervention Via Femoral ArteryChina
-
Diagram B.V.RecruitingCoronary Artery DiseaseBelgium, Poland, Slovakia